Tango Therapeutics

Tango Therapeutics, Inc. operates as a biotechnology company, which engages in discovering and delivering precision cancer medicines. Its primary program is TNG908, a protein arginine methyl transferase 5 inhibitor that is being developed as a treatment for cancers with MTAP deletions. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Cambridge, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.

- TNG908 IND cleared by FDA, Phase 1/2 trial expected to start in 1H 2022

Tango Therapeutics Announces Clearance of TNG908 IND by FDA and Recent Pipeline Progress Updates

- Strong cash position of $504 million supports advancing discovery and clinical pipeline into second half of 2024 -

Tango Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights

CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced two recent senior management appointments: Marc Rudoltz, M.D., as Chief Medical Officer, and Doug Barry, J.D., as General Counsel.

Tango Therapeutics Announces Appointment of Dr. Marc Rudoltz as Chief Medical Officer and Doug Barry as General Counsel

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been selected for presentation as virtual posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on October 7 – 10, 2021. “The preclinical data being presented today highlight the potential applicability of synthetic letha

Tango Therapeutics Announces Presentation of Preclinical Data on Lead Program and Discovery Platform in Five Abstracts Accepted at AACR-NCI-EORTC 2021

Wedbush initiated coverage of Tango Therapeutics Inc (NASDAQ: TNGX) with an Outperform rating and a $12 price target.  Analyst Robert Driscoll believes Tango's unique synthetic lethality approach is differentiated.

Three Analysts Initiate Coverage On This Newly Listed Precision Oncology Firm

News for Tango Therapeutics Stock (TNGX)